ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2791

Targeting Micro-RNAs Derived from Extracellular Vesicles to Inhibit of TLR7 and TLR8 Signaling Suppresses Inflammation in a Novel Human-Mouse Chimeric Model of Systemic Lupus Erythematosus

Nicholas A. Young1, Giancarlo R. Valiente2, Holly Steigelman3, Jeffrey Hampton4 and Wael N. Jarjour5, 1Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 2Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, 3The Ohio State University, Columbus, OH, 4Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, 5Department of Rheumatology/Medicine, Ohio State University, Columbus, OH

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Animal models, innate immunity, Systemic lupus erythematosus (SLE), therapy and toll-like receptors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Animal Models - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease displaying a heavy female predominance during reproductive years. We have previously shown that toll-like receptor (TLR)7 and TLR8 are significantly up-regulated in peripheral blood mononuclear cells (PBMCs) of SLE patients and further induced with estrogen treatment. Conventionally, TLR7 and TLR8 binding to single-stranded RNA of viral origin to stimulate innate inflammatory responses, but recent studies have discovered that specific micro-RNA (miR) sequences can activate these receptors following packaging and secretion via extracellular vesicles (EVs). Our objective in this study was to explore the therapeutic potential of using a cocktail of miR antagonists to block TLR7 and TLR8 inflammatory pathways induced by EV-derived miRs in SLE.

Methods:  PBMCs were isolated from active SLE patients and adoptively transferred into immunodeficient NOD-scid IL-2rγ (null) mice to produce chimeras containing PBMCs from SLE patients using a similar protocol we have previously established for Sjöjren’s syndrome. Prior to transfer, PBMCs were treated with a cocktail of several locked nucleic acid miR antagonists or nonsense, scrambled RNA controls prior to injection. Blood was collected for both flow cytometry and cytokine analysis and tissues were processed for histopathological examination by H&E and immunohistochemistry.

Results:  Human T-cells (CD4+ and CD8+), B-cells, monocytes, and NK cells were all successfully recovered from whole blood of chimeric mice at similar levels in both treatment groups 21 days after adoptive transfer. However, inhibition with miR antagonists reduced levels of human IL-2, IL-6, IL-10, and TNF-α relative to scramble (control) treatment. While histopathological analysis revealed little to no inflammation in the skin and ear with either treatment, miR antogonists inhibited the robust responses detected with scramble RNA (control) treatment in the small intestine, liver, and kidney. Further characterization of infiltrates by immunohistochemistry confirmed the presence human CD3+ T-cells.

Conclusion:  These data establish a novel human-mouse model to study SLE and provide an experimental platform to further explore the therapeutic potential of suppressing EV-encapsulated miRs that trigger TLR7 and TLR8 signaling.


Disclosure: N. A. Young, None; G. R. Valiente, None; H. Steigelman, None; J. Hampton, None; W. N. Jarjour, None.

To cite this abstract in AMA style:

Young NA, Valiente GR, Steigelman H, Hampton J, Jarjour WN. Targeting Micro-RNAs Derived from Extracellular Vesicles to Inhibit of TLR7 and TLR8 Signaling Suppresses Inflammation in a Novel Human-Mouse Chimeric Model of Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/targeting-micro-rnas-derived-from-extracellular-vesicles-to-inhibit-of-tlr7-and-tlr8-signaling-suppresses-inflammation-in-a-novel-human-mouse-chimeric-model-of-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeting-micro-rnas-derived-from-extracellular-vesicles-to-inhibit-of-tlr7-and-tlr8-signaling-suppresses-inflammation-in-a-novel-human-mouse-chimeric-model-of-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology